What is it about?
This paper is a systematic review and meta-analysis examining the use of fenofibrate as an adjuvant to phototherapy in treating unconjugated neonatal hyperbilirubinemia. It analyzes the effects on total serum bilirubin levels and phototherapy duration. The study found that fenofibrate may help reduce bilirubin levels and shorten phototherapy time.
Featured Image
Photo by Alexander Grey on Unsplash
Why is it important?
This study is important because it explores the potential of fenofibrate to enhance phototherapy, a common treatment for neonatal jaundice. By reducing bilirubin levels faster and shortening phototherapy duration, it could lower hospitalization time, healthcare costs, and associated risks, benefiting both newborns and healthcare systems.
Perspectives
Writing this article was a rewarding experience as it allowed us to collaborate across multiple hospitals and cities, bringing together diverse expertise. This research has sparked interest from neonatal care groups, expanding our involvement in improving treatments for neonatal jaundice and reducing its global burden.
Ari Viandri Wismananda
Universitas Muhammadiyah Malang
Read the Original
This page is a summary of: Use of fenofibrate as adjuvant to phototherapy in unconjugated neonatal hyperbilirubinemia: A systematic review and meta-analysis of randomized controlled trials, Journal of Neonatal-Perinatal Medicine, October 2024, IOS Press,
DOI: 10.3233/npm-230189.
You can read the full text:
Resources
Contributors
The following have contributed to this page
